410 related articles for article (PubMed ID: 36555792)
1. The Microbiome in Systemic Sclerosis: Pathophysiology and Therapeutic Potential.
Kim S; Park HJ; Lee SI
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555792
[TBL] [Abstract][Full Text] [Related]
2. Gut microbiota profile in systemic sclerosis patients with and without clinical evidence of gastrointestinal involvement.
Patrone V; Puglisi E; Cardinali M; Schnitzler TS; Svegliati S; Festa A; Gabrielli A; Morelli L
Sci Rep; 2017 Nov; 7(1):14874. PubMed ID: 29093509
[TBL] [Abstract][Full Text] [Related]
3. Congruent microbiome signatures in fibrosis-prone autoimmune diseases: IgG4-related disease and systemic sclerosis.
Plichta DR; Somani J; Pichaud M; Wallace ZS; Fernandes AD; Perugino CA; Lähdesmäki H; Stone JH; Vlamakis H; Chung DC; Khanna D; Pillai S; Xavier RJ
Genome Med; 2021 Feb; 13(1):35. PubMed ID: 33648559
[TBL] [Abstract][Full Text] [Related]
4. Gut Microbiota Aberration in Patients of Systemic Sclerosis and Bleomycin-Induced Mice Model.
Tang J; Zhou X; Wu X; Lin S; Ming B; Zhong J; Wang B; Dong L
Front Cell Infect Microbiol; 2021; 11():647201. PubMed ID: 34123867
[TBL] [Abstract][Full Text] [Related]
5. The microbiome and systemic sclerosis: A review of current evidence.
Tan TC; Noviani M; Leung YY; Low AHL
Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101687. PubMed ID: 33849778
[TBL] [Abstract][Full Text] [Related]
6. A review and roadmap of the skin, lung and gut microbiota in systemic sclerosis.
Teaw S; Hinchcliff M; Cheng M
Rheumatology (Oxford); 2021 Dec; 60(12):5498-5508. PubMed ID: 33734316
[TBL] [Abstract][Full Text] [Related]
7. Intestinal microbiome in scleroderma: recent progress.
Volkmann ER
Curr Opin Rheumatol; 2017 Nov; 29(6):553-560. PubMed ID: 28719392
[TBL] [Abstract][Full Text] [Related]
8. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
9. Update on the Gastrointestinal Microbiome in Systemic Sclerosis.
Bellocchi C; Volkmann ER
Curr Rheumatol Rep; 2018 Jun; 20(8):49. PubMed ID: 29943234
[TBL] [Abstract][Full Text] [Related]
10. Dysbiosis and Gut Microbiota Modulation in Systemic Sclerosis.
Lemos MPC; Zucoloto TG; Oliveira MC; de Oliveira GLV
J Clin Rheumatol; 2022 Mar; 28(2):e568-e573. PubMed ID: 34030162
[TBL] [Abstract][Full Text] [Related]
11. Animal models in systemic sclerosis: an update.
Bi X; Mills T; Wu M
Curr Opin Rheumatol; 2023 Nov; 35(6):364-370. PubMed ID: 37605874
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of fecal microbiota transplantation in the treatment of systemic sclerosis: A protocol for systematic review and meta analysis.
Zhang S; Lv J; Ren X; Hao X; Zhou P; Wang Y
Medicine (Baltimore); 2020 Jul; 99(28):e21267. PubMed ID: 32664182
[TBL] [Abstract][Full Text] [Related]
13. A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis.
Taroni JN; Greene CS; Martyanov V; Wood TA; Christmann RB; Farber HW; Lafyatis RA; Denton CP; Hinchcliff ME; Pioli PA; Mahoney JM; Whitfield ML
Genome Med; 2017 Mar; 9(1):27. PubMed ID: 28330499
[TBL] [Abstract][Full Text] [Related]
14. Current advances in the treatment of systemic sclerosis.
Bukiri H; Volkmann ER
Curr Opin Pharmacol; 2022 Jun; 64():102211. PubMed ID: 35447517
[TBL] [Abstract][Full Text] [Related]
15. Early inflammatory players in cutanous fibrosis.
Raker V; Haub J; Stojanovic A; Cerwenka A; Schuppan D; Steinbrink K
J Dermatol Sci; 2017 Sep; 87(3):228-235. PubMed ID: 28655471
[TBL] [Abstract][Full Text] [Related]
16. Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis.
Stenström M; Nyhlén HC; Törngren M; Liberg D; Sparre B; Tuvesson H; Eriksson H; Leanderson T
J Dermatol Sci; 2016 Jul; 83(1):52-9. PubMed ID: 27156795
[TBL] [Abstract][Full Text] [Related]
17. Cause or effect? Interpreting emerging evidence for dysbiosis in systemic sclerosis.
Denton CP; Murray C
Arthritis Res Ther; 2019 Mar; 21(1):81. PubMed ID: 30917857
[TBL] [Abstract][Full Text] [Related]
18. PDGF/PDGFR: A Possible Molecular Target in Scleroderma Fibrosis.
Paolini C; Agarbati S; Benfaremo D; Mozzicafreddo M; Svegliati S; Moroncini G
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409263
[TBL] [Abstract][Full Text] [Related]
19. Type I interferon dysregulation in Systemic Sclerosis.
Skaug B; Assassi S
Cytokine; 2020 Aug; 132():154635. PubMed ID: 30685202
[TBL] [Abstract][Full Text] [Related]
20. Animal models of scleroderma: recent progress.
Marangoni RG; Varga J; Tourtellotte WG
Curr Opin Rheumatol; 2016 Nov; 28(6):561-70. PubMed ID: 27533324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
